Sexually Transmitted Infections (STIs) Global Market Report 2024

The global sexually transmitted infections (stis) market has grown rapidly in recent years. It will grow from $56.17 billion in 2023 to $63.69 billion in 2024 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to behavioral factors, education and awareness, healthcare access, antibiotic development.

The global sexually transmitted infections (stis) market is expected to see rapid growth in the next few years. It will grow to $100.66 billion in 2028 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to emerging sti strains, vaccination initiatives, telemedicine and at-home testing, sexual health equity. Major trends in the forecast period include rise of antimicrobial resistance, pre-exposure prophylaxis (prep), sti self-management, enhanced sexual education.

Government-driven initiatives are playing a pivotal role in fueling the growth of the sexually transmitted infections (STIs) market. These government initiatives encompass a range of programs and policies aimed at raising awareness of STIs and are expected to be a driving force behind the market's expansion. These programs are specifically designed to address the challenges associated with STIs and typically involve allocating funds for public education campaigns to increase STI awareness. Additionally, government initiatives may include the development of vaccines to prevent certain STIs and the provision of free or low-cost screening and testing services. A notable example is the Disease Intervention Specialist (DIS) program launched by the Springfield-Greene County Health department in April 2023, in collaboration with the Missouri Department of Health and Senior Services (Missouri DHSS). This program focuses on countering the increasing prevalence of sexually transmitted infections, with a primary emphasis on syphilis and HIV. The DIS program involves experts who proactively reach out to individuals who have tested positive for these infections, facilitating access to treatment and ensuring contact tracing to raise awareness about potential infection. Therefore, government initiatives are expected to be a driving factor for the growth of the sexually transmitted infections (STIs) market.

The sexually transmitted infections (STIs) market is also witnessing growth due to the rising prevalence of unprotected sex. This shift in behavior indicates a trend where individuals engage in sexual activities without the use of protective measures like condoms, contributing to the increased transmission of STIs. As per data from the Centers for Disease Control and Prevention (CDC) in the United States, 30% of high school students had engaged in sexual intercourse in 2021. Alarmingly, 48% of these students did not use condoms during their most recent sexual encounter, and only 5% had been tested for sexually transmitted diseases within the past year. This culture of unprotected sex is driving the growth of the sexually transmitted infections (STIs) market.

High treatment costs are adversely impacting the growth of the sexually transmitted infections market during the forecast period. The elevated costs of treatment can exacerbate health disparities, as individuals with limited financial resources may face significant obstacles to accessing timely and effective STI care. This can contribute to disparities in STI prevalence and outcomes. For example, according to the American Hospital Association, a professional organization, hospital prices increased by 2.1% over the year leading up to February 2022. Therefore, the high cost of treatment is impeding the growth of the sexually transmitted infections market.

Major companies within the sexually transmitted infections (STIs) market are pioneering innovative products that incorporate fluorescent PCR technology to gain a competitive edge in the market. Fluorescent PCR (Polymerase Chain Reaction) technology is a molecular biology technique used to detect and quantify specific DNA sequences in a biological sample. For instance, in March 2023, Jiangsu Bioperfectus Technologies Co. Ltd., a China-based provider of molecular diagnostic solutions, introduced two new polymerase chain reaction (PCR) kits including the Mycoplasma Hominis Real-Time PCR Kit and the Treponema Pallidum Real-Time PCR Kit. These kits offer a comprehensive PCR solution for the early diagnosis of sexually transmitted infections, which affect a significant population. The BioPerfectus Mycoplasma Hominis Real-Time PCR Kit is a reagent that utilizes fluorescent PCR technology to detect Mycoplasma hominis in human male urethral swabs, female cervical or vaginal swabs, and urine samples. The BioPerfectus Treponema Pallidum Real-Time PCR Kit is designed to detect treponema pallidum nucleic acid in human serum and plasma.

In February 2023, Caraway Health, a US-based provider of digital healthcare services for Generation Z, entered into a partnership with Ash Wellness Inc. The collaboration addresses the surge in sexually transmitted infections (STIs) on university campuses among Generation Z. This partnership equips Generation Z with the tools necessary to prioritize their sexual well-being on their own terms. Ash Wellness Inc. is a US-based provider of remote diagnostic solutions, including home HIV and STI testing.

Major players in the sexually transmitted infections (stis) market are Pfizer Inc., Johnson & Johnson, Roche Holdings AG, Merck & Co Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy's Laboratories, Wockhardt Ltd., Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd.

North America was the largest region in the sexually transmitted infection (STIs) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sexually transmitted infections (STIs) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the sexually transmitted infections (STIs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of sexually transmitted infections (STIs) include human immunodeficiency virus (HIV), human papillomavirus (HPV), gonorrhea, syphilis, and others. Human Immunodeficiency Virus (HIV) is a virus that affects the body's immune system by targeting a specific type of white blood cell that plays a crucial role in resisting infections. Various treatments, including antibiotics and antivirals, are available, with testing conducted in diverse settings such as laboratory testing and point-of-care (POC) testing. These treatments are administered via oral, parenteral, and other routes and are commonly provided in hospitals, specialty clinics, homecare, and other healthcare settings.

This report provides sexually transmitted infections (STIs) market statistics, including sexually transmitted infections (STIs) industry global market size, regional shares, competitors with a sexually transmitted infections (STIs) market share, detailed sexually transmitted infections (STIs) market segments, market trends and opportunities and any further data you may need to thrive in the sexually transmitted infections (STIs) industry. This sexually transmitted infections (STIs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sexually transmitted infections (STIs) market consists of revenues earned by entities by providing services such as treatment, testing, awareness programs and diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The sexually transmitted infections (STIs) market also includes the sales of treatments such as testing kits, vaccines and medication. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.